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Edited by Masayuki MiyasakaAbstract Cytokine-induced suppressor of cytokine signaling
(SOCS) proteins function as feedback inhibitors of cytokine
receptor signaling by inhibiting the Janus kinase–signal trans-
ducer and activator of transcription (JAK–STAT) signal trans-
duction pathway. In this report, microtubule-associated protein
1S (MAP1), a member of the MAP1 family, was identiﬁed as
a novel SOCS3 interacting protein. MAP1S could bind with
microtubules and actin, and decorated and stabilized microtu-
bules. A perinuclear co-localization was discovered between
MAP1S and SOCS3. In MAP1S deﬁcient macrophages, inhibi-
tion of SOCS3 on STAT3 phosphorylation can be partially hin-
dered in the presence of interleukin-6 (IL-6) and
lipopolysaccharide (LPS). The microtubule-depolymerizing drug
nocodazole also disrupted the inhibitory activity of the SOCS3
protein. These results suggest that the interaction of SOCS3
with MAP1S and the integrity of the microtubule cytoskeleton
play an important role in the negative regulation of SOCS3 on
IL-6 signaling.
Structured summary:
MINT-6796998:
SOCS3 (uniprotkb:O35718) physically interacts (MI:0218)
with MAP1S (uniprotkb:Q66K74) by anti bait coimmunopre-
cipitation (MI:0006)
MINT-6796957:
SOCS3 (uniprotkb:O14543) physically interacts (MI:0218)
with MAP1S (uniprotkb:Q66K74) by pull down (MI:0096)
MINT-6796909, MINT-6796875, MINT-6796894, MINT-
6796936:
SOCS3 (uniprotkb:O14543) physically interacts (MI:0218)
with MAP1S (uniprotkb:Q66K74) by two hybrid (MI:0018)
MINT-6797017:
MAP1S (uniprotkb:Q8C052) physically interacts (MI:0218)
with SOCS3 (uniprotkb:O35718) by anti bait coimmunoprecip-
itation (MI:0006)
MINT-6796979:Abbreviations: SOCS, suppressor of cytokine signaling; MAP1,
microtubule-associated protein 1; LPS, lipopolysaccharide; IL-6,
interleukin-6; JAK, Janus kinase; STAT, signal transducer and
activator of transcription; CIS, cytokine-inducible Src homology 2-
containing protein; KIR, kinase inhibitory region; TLR, toll like
receptor; MTOC, microtubule organizing center; RASSF1A, Ras
association domain family 1, isoform A; VCY2, variably charged
protein Y2; APRE, acute-phase response element; IRS-1, insulin
receptor substrate 1; GHR, growth hormone receptor; GST, glutathi-
one S-transferase
*Corresponding authors. Fax: +86 27 6875 4131 (Y. Qi).
E-mail addresses: mvlwu@whu.edu.cn (Y. Liu), qiyipeng@whu.
edu.cn (Y. Qi).
0014-5793/$34.00  2008 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2008.10.055MAP1S (uniprotkb:Q66K74) and SOCS3 (uniprotkb:O14543)
colocalize (MI:0403) by ﬂuorescence microscopy (MI:0416)
 2008 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords: SOCS3; MAP1S; Microtubule cytoskeleton; IL-6;
Negative regulation1. Introduction
Cytokines consist of a large family of secreted proteins,
including pro-inﬂammatory agents, growth hormone and
erythropoietin, that utilize the Janus kinase–signal transducer
and activator of transcription (JAK–STAT) signal transduc-
tion pathway to mediate many of their key physiologic and
pathologic actions including cytokine-mediated inﬂammation,
immunoregulation, hematopoiesis and growth. Suppressor of
cytokine signaling (SOCS) proteins have been involved in cyto-
kine signaling as a family of negative regulators [1]. The SOCS
family comprises eight proteins, including SOCS1–SOCS7 and
cytokine-inducible Src homology 2-containing protein (CIS)
[2]. All the members contain a central SH2 domain and a con-
served C-terminal SOCS box. However, the mechanisms vary
on inhibition of cytokine signaling [3–5].
SOCS3 is thought to be important for down regulation of
interleukin-6 (IL-6), leptin, erythropoietin and insulin signal-
ing pathways [6–9]. SOCS3 protein binds to the activation loop
of Jak family tyrosine kinases and inhibits their kinase activity
through its SH2 domain and kinase inhibitory region (KIR).
The activated signaling proteins targeted with SOCS proteins
have been taken for degradation by the proteasome. IL-6, as
a proinﬂammatory cytokine, strongly induces activation of
STAT1 and STAT3 through binding with its receptor gp130.
The phosphorylation of STATs can be inhibited by lipopoly-
saccharide (LPS) induced SOCS3 [10]. Gene targeting experi-
ments have shown illuminating information with respect to
SOCS function [11,12]. Both mice deﬁcient in SOCS3 and
transgenic embryos that constitutively overexpress SOCS3
died during embryogenesis. It is due to that SOCS3 is critical
in LIF signaling in altered trophoblast diﬀerentiation [13].
However, the details of SOCS3 function in target proteins
for regulation are not well understood.
MAP1S is reported as a novel member of the microtubule-
associated protein 1 (MAP1) family and plays a role in stabil-
ization of microtubule, anchoring the microtubule organizing
center (MTOC) to the centrosome and regulation of mitotication of European Biochemical Societies.
4016 T. Zou et al. / FEBS Letters 582 (2008) 4015–4022progression [14]. The MAP1 family is a class of microtubule-
binding proteins, consists of three members, MAP1A, MAP1B
and a short form, MAP1S. MAP1A and MAP1B are expressed
predominantly in the nervous system and thought to mediate
interactions of the microtubule-based cytoskeleton in neural
development and function. The characteristic structural orga-
nization of mammalian MAP1S, which is composed of hea-
vy-chain and light chain subunits, requires proteolytic
cleavage of a precursor polypeptide. Similar to microtubule-
associated proteins tau and MAP2, MAP1S selectively binds
to double stranded DNA by its microtubule-binding domain
[15]. It has been identiﬁed that several proteins interact with
MAP1S. MAP1S anchors Ras association domain family 1,
isoform A (RASSF1A) to the centrosomes, which is a novel tu-
mor suppressor gene that is found to be inactivated in more
than 40 types of cancer [16]. Variable charged protein Y2
(VCY2) is a testis-speciﬁc protein and it has been proposed
that the involvement of VCY2 in the cytoskeletal network
through interaction with MAP1S [17]. It has recently been
shown that MAP1S potentially links the N-methyl-D-aspartate
receptor subunit NR3A to the cytoskeleton and may stabilize
NR3A-containing receptors at the synapse [18].
In the study presented here, we used SOCS3 protein as bait
for yeast two-hybrid screens in a human fetal cDNA library
and identiﬁed microtubule-associated protein MAP1S as a po-
tential SOCS3 interacting protein. We found that MAP1S
could change the cellular localization of SOCS3 protein by
increasing the translocation from the nucleus to cytoplasm.
In the IL-6 signaling, inhibition of STAT3 phosphorylation
by SOCS3 was delayed in MAP1S deﬁcient macrophage. Fur-
thermore, phospharylation of STAT3 was also enhanced by
microtubule depolymerization with nocodazole treatment.
These results conﬁrmed that the interaction between SOCS3
and MAP1S, and moreover, the integrity of microtubule cyto-
skeleton was critical for normal function of SOCS3.2. Materials and methods
2.1. Antibodies and reagents
Anti-hemagglutinin was from Roche Diagnostics. Anti-FLAG and
anti-c tubulin antibodies, lipopolysaccharide (LPS) and nocodazole
were from Sigma. Anti-GST and anti-SOCS3 antibodies were from
Ptglab Co. Anti-STAT3 and anti-phosphorylated STAT3 antibodies
were from cell signaling. Anti-b actin, horseradish peroxidase-conju-
gated anti-mouse and anti-rabbit IgG antibodies were from Santa
Cruz. Anti-MAP1S antibody was prepared by using puriﬁed his-
tagged C-terminal of MAP1S as an antigen to immunize rabbits. Alexa
Fluor 594 goat anti-rabbit IgG antibodie was from Invitrogen. Recom-
binant IL-6 was from Peprotech.
2.2. cDNAs, plasmids and proteins
The full-length SOCS3 gene and truncate mutants were ampliﬁed by
PCR and cloned into pGBKT7, pGEX6P1, pEGFP-C1, pCMV-HA,
pM vectors respectively. GST fusion SOCS3 mutant proteins expressed
in Escherichia coli. BL21(DE3) were puriﬁed by using glutathione S-
transferase (GST) purifying system. MAP1S gene was cloned into
pGADT7, pCMV-Tag2, pCDNA 3.1(-), pVP16 vectors, respectively.
2.3. Cell culture and transfection
Hela cells and human embryonic kidney 293T cells were kept in Dul-
beccos Modiﬁed Eagles Medium with 10% fetal calf serum. Murine
macrophage RAW264.7 cells were cultured in RPMI 1640 medium
with 10% fetal calf serum. Cells seeded in 24-well plate were transfected
with plasmid by using Lipofectamin 2000 (Invitrogen). The stable
transfection and expression of MAP1S in RAW264.7 cells were
selected with G418.2.4. Yeast two-hybrid screen
The full-length of human SOCS3 was cloned in pGBKT7 (Clontech)
vector. The fusion construct used as bait in the AH109 yeast strain
transformed with a human brain cDNA library in the pACT2 vector
for screening proteins interacting with SOCS3. Positive colonies were
then tested for b-galactosidase activity and sequenced.
2.5. GST pull-down assay
Approximately 2 mg GST fusion protein bound to agarose beads
was added to each lysate from 293T cells, followed by inbubation
for 2 h with gentle rotation. Beads were washed ﬁve times with wash
buﬀer, and proteins were eluted with elution buﬀer and analyzed.
2.6. Coimmunoprecipitation and immunoblot
Cells transfected with various plasmids were incubated for 36 h be-
fore analysis. Cells were lysed with MPERTM protein extraction re-
agent (Pierce), and equal amounts of samples were loaded for SDS–
PAGE. Immunoblotting was carried out on nitrocellulose membranes
(Millipore). We carried out immunoprecipitation using an MPERTM
immunoprecipitation kit (Pierce).
2.7. Mammalian two-hybrid assays
293T cells were transfected with pM-SOCS3, pVP16-MAP1 S and
the Gal4-Luc reporter gene and equal amount of b-gal plasmid as an
internal control. Luciferase activity was measured 24 h after transfec-
tions.
2.8. RNA interference
The RNAi pSUPER system (OligoEngine) was used. The diﬀerent
pSUPER recombinant vectors were constructed by inserting 64-mer
synthetic DNA oligonucleotides that encode two 19-nucleotide (nt) re-
verse complements with homology to a portion of the target gene. For
the two MAP1S siRNA construct, target sequences were nt 1650–1669
and nt 2750–2769. For the EGFP siRNA construct, target sequence
was nt 158–176.
2.9. Immunoﬂuorescence
Hela cells were harvested 48 h post-transfection and ﬁxed in either
4% paraformaldehyde for 15 min at 25 C. Cells ﬁxed in methanol were
washed with phosphatebuﬀered saline (PBS), blocked with 0.5% BSA
for 1 h at 25 C, incubated with primary antibody at 4 C overnight,
washed three times with PBS, incubated with secondary antibody for
45 min at 25 C, washed ﬁve times with PBS, and mounted onto a slide
with 50% glycerol. Confocal images were captured with a Leica TCS
SP2 AOBS MP.2.10. STAT3 report assay
Cells were transfected with 1 lg of the STAT3-responsive acute-
phase response element (APRE) luciferase reporter and 0.1 lg of the
pRL-TK Renilla reporter (Promega) in combination with the indicated
expression plasmids. Cells were harvested after the indicated periods of
time, and the ﬁreﬂy luciferase levels were determined using the dual-
luciferase reporter assay system (Promega).3. Results
3.1. SOCS3 interacts with MAP1S in vivo and in vitro
To further investigate the suppression cytokine signal trans-
duction mechanism of SOCS3 protein, we performed yeast
two-hybrid assay with SOCS3 as bait to screen a human fetal
brain cDNA library. The plasmid DNA isolated from positive
yeast colonies was transformed into E. coli and sequenced.
Two of these 23 clones encoded the light chain of MAP1S
(814aa-1059aa, 765aa-980aa) (Fig. 1A).
To conﬁrm the interaction between SOCS3 and MAP1S,
we performed in vitro GST pull-down experiment. As shown
in Fig. 1B, MAP1S protein was precipitated by GST-SOCS3
but not by the GST-tag alone. To determine if this interaction
Fig. 1. Microtubule associated protein1S interacts with SOCS3 protein in vitro and vivo. (A) Schematic of MAP1S protein. The full-length of
MAP1S can be cleavaged into heavy-chain and light chain. MAP1S consists of two conserved microtubule-binding domain and an actin binding
domain. Two positive clones encode the C-terminal of MAP1S. (B) MAP1S was co-precipitated with GST-SOCS3 but not with the GST-tag alone.
(C) Mouse macrophage RAW264.7 cells were stimulated with LPS. Endogenous MAP1S could be co-immunoprecipitated with induced SOCS3
protein. (D) Mouse macrophage RAW264.7 cells transfected with FLAG-MAP1S were stimulated with LPS. Whole-cell lysates were immunoblotted
with antibodies to SOCS3, FLAG tag or b-actin. MAP1S was co-immunoprecipitated with SOCS3 protein at 1, 2, 4, 8 h after stimulation.
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RAW264.7 were stimulated with or without LPS. It was
showed that LPS-induced SOCS3 protein had been binding
with MAP1S protein. Moreover, the interaction between
MAP1S and SOCS3 was time-dependent in RAW264.7 cells
stable transfected with Flag-tagged MAP1S under the LPS
stimulation. SOCS3 protein expression was induced 0.5h after
LPS stimulation and MAP1S was precipitated with endoge-
nous SOCS3 at 1, 2, 4 and 8 h (Fig. 1C and D). Similarly,
mammalian two-hybrid assay suggested there was SOCS3-
MAP1S interaction in living cells (Fig. 2C). These results
indicate that the association between MAP1S and SOCS3 is
speciﬁc in vitro and in vivo.3.2. The BG loop of SOCS3 is essential for MAP1S interaction
SOCS3 contains an N-terminal region, a KIR, a N-extended
SH2 subdomain (N-ESS), a central SH2 domain, a PEST mo-
tif, a C-extended SH2 subdomain (C-ESS) and a C-terminal
SOCS box [19]. KIR and SH2 domain are responsible for
the interaction with the JAKs or blocking STAT access to
docking sites on the receptors. SOCS box is essential for pro-
tein degradation through interacting with an E3-ligase com-
plex [4,20]. To determine which domain of SOCS3 is
required for its interaction with MAP1S protein, series of mu-
tants were created. All truncated mutants were constructed in
pGBKT7 vector and their interactions with MAP1S were mea-
sured by yeast two-hybrid assay (Fig. 2A). We found that
Fig. 2. C-ESS domain of SOCS3 is required for MAP1S interaction. (A) Schematic picture of SOCS3 showing the diﬀerent mutants of SOCS3 tested
for interaction with MAP1S by yeast two-hybrid system. Two mutants lacked the C-ESS domain can not bind with MAP1S. (B) GST-tagged SOCS3
mutants was puriﬁed and incubated with cell lysates of 293T cell transfected with MAP1S. MAP1S was co-precipitated with mutants except SOCS3
DC1 and DC2. (C) Two-hybrid assays for protein–protein interactions in living cells. 293T cells were transiently transfected with the Gal4-reporter
together with the indicated constructs, and luciferase activity was measured 24 h later.
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had no inﬂuence on the interaction with MAP1S protein, but
the BG loop (C-ESS), located downstream of the PEST insert,
is essential for binding MAP1S protein. In addition, we per-
formed the GST pull-down experiment and found that
MAP1S protein was not precipitated by the SOCS3 truncated
protein which lacked the C-ESS domain (Fig. 2B). In the mam-
malian two-hybrid assay, the results were consistent with the
in vitro binding data, which indicated MAP1S interacted with
all SOCS3 truncated mutants except SOCS DC1 and DC2 mu-
tants (Fig. 2C), and BG loop of SOCS3 is essential for MAP1S
interaction.
3.3. MAP1S changes the cellular localization of SOCS3 protein
As MAP1S is a microtubule-binding protein, several pro-
teins which interact with MAP1S has the same localization
in cytoplasm [16–18]. So we detected the localization of SOCS3
protein in presence of MAP1S. Hela cells were transiently
transfected with either the EGFP construct or the EGFP-
SOCS3 and visualized by confocal microscope. In contrast to
diﬀuse cytoplasmic ﬂuorescence localization with EGFP
(Fig. 3A), the EGFP tagged SOCS3 localized in both cyto-
plasm and nucleus (Fig. 3B). We stained Hela cells with anti-
c-tubulin as a marker for microtubule organizing complex
(MTOC) and found some SOCS3 protein could co-localize
with MTOC. Surprisingly, the GFP ﬂuorescence was found
predominantly in the cytoplasm and less in the nucleus when
Hela cells were transfected with EGFP-SOCS3, DN, DC and
FLAG-MAP1S respectively (Fig. 3C–E). However, the locali-
zation of EGFP-SOCS3 DC1 protein which could not interact
with MAP1S was both in cytoplasm and in nucleus (Fig. 3F).
As shown in Fig. 3G, the fractionated proteins from cytoplasm
and nucleus were isolated and the expression of SOCS3 and
truncated proteins was detected. These results indicated that
the cellular localization of SOCS3 protein was changed by
overexpressed MAP1S. Thus, MAP1S may be the linker for
SOCS3 to localize with microtubule cytoskeleton in cytoplasm.Fig. 3. Colocalization of SOCS3 with FLAG-tagged MAP1S. Hela
cells were transfected with pEGFP (A) or EGFP-SOCS3 (B) and
visualized by confocal microscopy. Cells were visualized for GFP or
were stained with anti-c-tubulin followed by Texas Red- anti-mouse
antibody to visualize the MTOC. Hela cells were co-transfected with
EGFP-SOCS3 (C), SOCS3 DN (D), DC (E), DC1 (F) and Flag-tagged
MAP1S and visualized by confocal microscopy. Cells were visualized
for GFP and stained with anti-FLAG followed by anti-rabbit
antibody-Alexa Fluor 594. (G) Cytoplasmic and nuclear fractions of
the co-transfected cells were prepared and immunoblotted with
antibodies to SOCS3, FLAG tag and lamin B.3.4. MAP1S participates in the process of SOCS3 in regulating
IL-6 signaling
To investigate the functional relationship between SOCS3
and MAP1S, we used RNA interference to knock down
MAP1S expression. MAP1S protein expression level was eﬃ-
ciently reduced by two diﬀerent siRNA constructs against
the MAP1S (Fig. 4A). It has been shown SOCS3 is a potential
physiological negative regulator of IL-6 signaling. The high-
aﬃnity interaction of SOCS3 with gp130 through its SH2 do-
main and with JAKs through its KIR results in hindered IL-6
signaling. To determine whether MAP1S inﬂuences the func-
tion of SOCS3 in regulating IL-6 signaling, we analyzed the
phosphorylation state of STAT3 in MAP1S deﬁcient macro-
phages. In both control and MAP1S deﬁcient macrophages,
expression of SOCS3 protein was induced 1h after LPS stimu-
lation. At the same time, IL-6 mediated activation of STAT3
was strongly suppressed in wide-type macrophages by SOCS3.
However, in MAP1S deﬁcient macrophages stimulated with
LPS, inhibition of STAT3 phosphorylation in IL-6 signaling
was delayed and hindered. Furthermore, we performed repor-
ter gene assay to detect activity of STAT3. SOCS3 inhibited
STAT3 transcription activity induced by IL-6 more eﬃciently
in wide-type macrophages than in MAP1S deﬁcient macro-
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in concert with SOCS3 activity in regulation of STAT3 phos-
phorylation induced by IL-6.
3.5. Integrity of the microtubule network is critical for the
inhibition of SOCS3 protein in IL-6 signaling
As mentioned above, MAP1S was able to change SOCS3
cellular localization, which also involved in the activity ofFig. 4. Depletion of MAP1S prolongs phosphorylation of STAT3 by IL-6. (A
264.7 cells with control siRNA or two siRNA constructs against MAP1S. b
transfected with control siRNA or siMAP1S-2 were stimulated with IL-6 (100
durations. Whole-cell extracts were immunoblotted with antibodies to phosp
STAT3-responsive luciferase reporter (APRE) was transfected into macroph
stimulation with IL-6 (100 ng/ml) or LPS (100 ng/ml), the luciferase activitySOCS3 in regulating IL-6 signal pathway. We presumed that
MAP1S is an adaptor that linked SOCS3 to microtubule cyto-
skeleton. Previous work has demonstrated that an intact
microtubule network is required for the turnover of SOCS1
protein [21]. The half-life of SOCS1 was prolonged by noco-
dazole, which is a microtubule depolymerizor that disrupts
the microtubule cytoskeleton and microtubule-dependent
transportion [22]. There lies a possibility that microtubule) Western blot analysis of MAP1S levels after 48h transfection of RAW
-actin was used as a loading control. (B) Macrophage RAW264.7 cells
ng/ml) in the presence or absence of LPS (100 ng/ml) for the indicated
ho-STAT3, STAT3, SOCS3 or MAP1S. (C) Construct containing the
age RAW264.7 with control siRNA and siMAP1S-2 expressed. After
was measured.
Fig. 5. Nocodazole hinders the inhibition of STAT3 phosphorylation.
(A) Macrophage RAW264.7 cells were treated with DMSO as a
control or nocodazole in the presence of LPS (100 ng/ml) and IL-6
(100 ng/ml) for the indicated durations. Whole-cell extracts were
immunoblotted with antibodies to phosphor-STAT3, STAT3, SOCS3
or b-actin. (B) Construct containing the STAT3-responsive luciferase
reporter (APRE) was transfected into macrophage RAW264.7 cells
with DMSO or nocodazole treatment. After stimulation with IL-6
(100 ng/ml) and LPS (100 ng/ml), the luciferase activity was measured.
T. Zou et al. / FEBS Letters 582 (2008) 4015–4022 4021cytoskeleton may play an important role in SOCS3 activity.
Therefore we went to ﬁnd whether SOCS3 negatively regulates
IL-6 signaling pathway in a microtubule cytoskeleton-depen-
dent manner. RAW264.7 macrophages with nocodazole treat-
ment were stimulated by LPS plus IL-6. As shown in Fig. 5, in
control macrophages treated with DMSO, SOCS3 protein con-
centration was up-regulated after stimulation with LPS plus
IL-6, and the phosphorylation of STAT3 was inhibited subse-
quently. However, when RAW264.7 cells were treated by
microtubule depolymerizor nocodazole, phosphorylation of
STAT3 was prolonged and the inhibition by SOCS3 protein
was impaired. Moreover, in reporter gene assay, the inhibition
of STAT3 transcription activity by SOCS3 was reduced in
nocodazole treated cells. These results indicated that microtu-
bule depolymerization resulted in down regulation of the activ-
ity of SOCS3.4. Discussion
In this study, we identify MAP1S as a novel SOCS3 binding
protein by screening human fetal brain cDNA library. This un-
ique interaction is conﬁrmed in vitro and vivo by GST pull-
down assay and co-immunoprecipitation assay. The BG loop
of SOCS3 protein, which has been proposed to bind to
gp130 with high-aﬃnity, locates downstream of its SH2 do-
main, and plays an essential role in binding with MAP1S.MAP1S is expressed in a wide range of tissues include neu-
rons and non-neuronal counterpart. However, endogenous
SOCS3 expression is very low. We test the exogenous SOCS3
localization. Confocal microscopy shows MAP1S and SOCS3
co-localizes in perinuclear cytoplasm in Hela cells. Overexpres-
sed MAP1S could change the cellular localization of SOCS3
protein from predominantly in nucleus to cytoplasm. It may
be demonstrated that MAP1S acts as an adaptor protein which
links SOCS3 protein to microtubule cytoskeleton. Recent data
have shown SOCS1 protein colocalize and biochemically copu-
rify with the microtubule organizing complex and its associ-
ated 20s proteasome [21]. This localization may be helpful
for SOCS proteins target cytokine signaling proteins for ubiq-
uitination and proteasomal degradation in a SOCS box depen-
dent manner.
Bacterial LPS triggers innate immune responses through the
Toll-like receptor 4. Regulation of toll like receptor (TLR) sig-
naling is a key step for inﬂammation, septic shock and innate/
adaptive immunity. Functioning as a transcription factor,
STAT3 participates in the signaling pathways for many cyto-
kines in various cells and organs that are regulated by the
SOCS family, including SOCS3. SOCS3 protein was strongly
induced by both IL-6 and IL-10 in the presence of LPS, but
selectively inhibited IL-6 signaling. Therefore lack of SOCS3
gene in macrophages resulted in suppression of TLR signaling
by hyperactivation of STAT3. We test activity of STAT3 in
MAP1S deﬁcient macrophage in presence of LPS and IL-6.
The phosphorylation of STAT3 is prolonged with MAP1S
knockdown and SOCS3 protein level is not inﬂuenced. The
inhibition mechanism of SOCS3 in IL-6 signaling pathway is
disrupted by MAP1S depletion. These results demonstrate that
MAP1S could take part in the way of SOCS3 down regulates
STAT3 activity and inhibits IL-6 signaling. The localization of
SOCS3 to microtubule cytoskeleton through MAP1S may be
essential for the negative regulation of cytokine signaling.
A microtubule-deploymerizing drug nocodazole is demon-
strated to inhibit the degradation of SOCS1 protein and delay
the protein turnover. However, we have not discovered noco-
dazole has any eﬀect on SOCS3 degradation. Nevertheless,
inhibition of STAT3 phosphorylation in IL-6 signaling is de-
layed by SOCS3 with nocodazole treatment. The result is con-
sistent with the data in MAP1S deﬁcient macrophages. It
indicates that in addition to binding with cytoskeleton through
microtubule-associated protein, the integrity of microtubule
network is required for the negative regulating mechanism of
SOCS3 protein.
Three diﬀerent ways for SOCS3 to inhibit cytokine signaling
pathway are proposed. First, SOCS3 protein inhibits compo-
nents of the cytokine signaling cascade through direct binding.
Second, SOCS3 protein binds to phosphorylated receptors and
prevents access to the signaling complex. The third way is that
SOCS3 targets signal transducers for proteasomal destruction.
It has been suggested some proteins targeted by SOCS3 is re-
lated to microtubule cytoskeleton. For example, insulin recep-
tor substrate 1 (IRS-1) binds to microtubule and microtubules
involves in insulin signaling pathway are demonstrated [23].
Two Jak family members, Tyk2 and Jak1, are targeted to
microtubule polymers through Jamip1 protein [24]. Growth
hormone receptor (GHR) is required for tubulin polymeriza-
tion and microtubule network stabilization [25]. It may imply
that microtubule network aﬀords a platform for signaling
complexes in the SOCS3 regulating process. Thus, MAP1S
4022 T. Zou et al. / FEBS Letters 582 (2008) 4015–4022anchors SOCS3 protein to the microtubules as a linker is nec-
essary for the regulation mechanism.
Our work suggests that both MAP1S depletion and microtu-
bule depolymerization could delay the inhibition of SOCS3 in
IL-6 signaling, and moreover, MAP1S may act as an adaptor
protein that links SOCS3 protein to microtubules. Microtu-
bules may facilitate signaling by serving as a platform for the
construction of larger signaling complexes and transportation
of inﬂammatory factors. Thus, the eﬃcient negative regula-
tion of cytokine signaling by SOCS3 is dependent on the integ-
rity of microtubule network.
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